What is Ingersoll Rand's biopharma — impairments?

Ingersoll Rand (IR) reported biopharma — impairments of $170.30M in Q2 2025.

What does biopharma — impairments mean?

The amount of value written off from assets in the biopharma segment due to a decline in their expected future worth.

Discontinued — last reported Q2 '25

Business Segments · Impairments

Biopharma — Impairments

Analysis

StatementSegment

CategoryRisk

SignalLower is better

VolatilityVolatile

First reportedQ2 2025

Last reportedQ2 2025

Rolls up toGoodwill impairment

How to read this metric

An increase indicates potential overpayment for past acquisitions or a deterioration in the competitive position of the biopharma business, while a decrease suggests stable asset valuations.

Detailed definition

This metric represents the non-cash charges recognized when the carrying value of assets associated with the biopharma b...

Peer comparison

Peers in the industrial and life sciences sectors typically report impairments sporadically; consistent or large impairments relative to segment revenue are viewed negatively by analysts.

Metric ID: ir_segment_biopharma_impairments

Historical Data

1 periods

	Q2 '25
Value	$170.30M

Similar Metrics at Other Companies

PfizerPFE View metric

WAT

Waters CorporationWAT View metric

Iron MountainIRM View metric

Thermo Fisher ScientificTMO View metric

TechnipFMCFTI View metric

Iron MountainIRM View metric

Frequently Asked Questions

What is Ingersoll Rand's biopharma — impairments?: Ingersoll Rand (IR) reported biopharma — impairments of $170.30M in Q2 2025.
What does biopharma — impairments mean?: The amount of value written off from assets in the biopharma segment due to a decline in their expected future worth.